研究单位：[1]Guangzhou Lupeng Pharmaceutical Company LTD.[2]Peking University Cancer Hospital & Institute[3]Anhui provincial cancer hospital,Hefei,Anhui,China[4]The first affiliated hospital of Anhui medical university,Hefei,Anhui,China[5]Peking University Third Hospital,Beijing,Beijing,China,100089[6]Beijing Cancer Hospital,Beijing,Beijing,China,100142[7]The first affiliated hospital of Chongqing mediacal university,Chongqing,Chongqing,China[8]Fujian Cancer Hospital,Fuzhou,Fujian,China[9]Fujian Medical university union hospital,Fuzhou,Fujian,China[10]The first affiliated hospital of Xiamen university,Xiamen,Fujian,China[11]Gansu provincial cancer hospital,Lanzhou,Gansu,China[12]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[13]Meizhou people'shospital,Meizhou,Guangdong,China[14]The First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,China[15]The fourth hospital of Hebei medical university,Shijia Zhuang,Hebei,China[16]Harbin First Hospital,Ha'erbin,Heilongjiang,China[17]Henan Cancer Hospital,Zhengzhou,Henan,China[18]Henan provincial people's hospital,Zhengzhou,Henan,China[19]The first affiliated hospital of Zhengzhou university,Zhengzhou,Henan,China[20]Hunan cancer hospital,Changsha,Hunan,China[21]Jiangsu cancer hospital,Nanjing,Jiangsu,China[22]Jiangsu province hospital,Nanjing,Jiangsu,China[23]The first affiliated hospital of Nanchang university,Nanchang,Jiangxi,China[24]The second hospital of dalian medical university,Dalian,Liaoning,China[25]Shengjing hospital of China medical university,Shenyang,Liaoning,China[26]The first hospital of China medical university,Shenyang,Liaoning,China[27]Qilu hospital of Shandong university,Jinan,Shandong,China[28]Shandong Cancer Hospital,Jinan,Shandong,China[29]West China School of Medicine,Chengdu,Sichuan,China[30]Tianjin Hematonosis Hospital,Tianjin,Tianjin,China[31]Tianjin medical university cancer hospital,Tianjin,Tianjin,China[32]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China[33]Affiliated hospital of hebei university,Baoding,China[34]Beijing Boren Hospital,Beijing,China[35]Beijing Friendship hospital,Beijing,China[36]The First Bethune Hospital of Jilin University,Changchun,China[37]Sichuan Cancer Hospital,Chengdu,China[38]The First People's Hospital of Foshan,Foshan,China[39]Nanfang Hospital, Southern Medical University,Guangzhou,China[40]Sun Yat-sen Memorial Hospital,Guangzhou,China[41]The First Affiliated Hospital of Soochow University,Suzhou,China[42]The first affiliated hospital of Wenzhou medical university,Wenzhou,China[43]Hubei Cancer Hospital,Wuhan,China[44]Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology,Wuhan,China
研究目的：
This is an open-label, single arm, multi-center Phase 2 study of oral LP-168 in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
